Genetically engineered nk cells and uses thereof
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- IMMUXELL BIOTECH LTD
- Filing Date
- 2024-12-06
- Publication Date
- 2026-06-09
AI Technical Summary
In current tumor immunotherapy, tumor cells escape TCR-T therapy by downregulating MHC class I molecules, resulting in poor treatment efficacy. CAR-NK cells can only recognize surface antigens and cannot recognize internal antigens, leading to unsatisfactory results in solid tumors.
By transducing the TCR-CD8α-CD3 complex onto the surface of NK cells, specific recognition of tumor cells can be achieved while retaining the killing effect of MHC class I molecules downregulating tumor cells. Nucleic acid constructs of TCR, CD8α, and CD3 are introduced into NK cells using a retroviral vector.
The prepared 051TCR-NK genetically engineered cells exhibit significant cytotoxicity against HLA-A*11:01 KRAS G12V mutant cells, and can specifically recognize and kill KRAS G12V mutant tumor cells, making them suitable for clinical treatment.
Smart Images

Figure HDA0005178408320000011 
Figure HDA0005178408320000021 
Figure HDA0005178408320000022